Contract awarded for products that bring improvement to the healthcare industry FORT WORTH, TX, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara MedTech,” “Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market, today announced that its BIASURGE® Advanced Surgical Solution (“BIASURGE”) product has receive ...

Core Insights - Sanara MedTech Inc. plans to launch OsStic Synthetic Injectable Structural Bio-Adhesive in the U.S. market in Q1 2027, following FDA clearance [1][2] - OsStic has received Breakthrough Device Designation from the FDA, indicating its potential to improve treatment for serious conditions [2] - The product is expected to be the first bone bioadhesive in the U.S. utilizing phosphoserine, α-TCP, and calcium silicate, offering significant advantages over traditional methods [2][3] Product Development and Regulatory Milestones - Sanara and Biomimetic Innovations Ltd (BMI) have achieved significant milestones in product development, clinical trials, and regulatory processes throughout 2025 [3] - The U.S. Patent and Trademark Office granted a patent for OsStic, ensuring protection of its key ingredients and applications until at least 2037 [3][6] - The partnership between Sanara and BMI includes an exclusive license and distribution agreement, enhancing Sanara's market position in orthopedic care [5][6] Market Need and Innovation - OsStic addresses critical limitations in current provisional fixation techniques, providing forty times stronger bonding than traditional calcium phosphate bone cement [2][3] - The product aims to meet the unmet clinical needs in complex joint reconstruction, offering a paradigm shift in treating previously non-repairable fractures [3] - Sanara's commitment to innovation is reflected in its collaboration with BMI to introduce OsStic as a new standard in bone bioadhesives [4]

Core Viewpoint - Sanara MedTech Inc. is participating in the Piper Sandler 37th Annual Healthcare Conference, presenting on December 3, 2025, to discuss its transformative technologies aimed at improving clinical outcomes and reducing healthcare costs in the surgical market [1] Company Overview - Sanara MedTech Inc. focuses on developing and commercializing technologies that enhance clinical outcomes while lowering healthcare expenditures in the surgical market [3] - The company markets and distributes a range of surgical products, including CellerateRX Surgical Activated Collagen Powder and FORTIFY TRG Tissue Repair Graft, primarily in the North American surgical tissue repair markets [3] - Sanara aims to be a leading provider of innovative surgical solutions and is committed to expanding its product offerings for patients in the United States [3]

Core Insights - Sanara MedTech Inc. has completed its evaluation of strategic alternatives for the Tissue Health Plus (THP) segment and has decided to discontinue THP operations to enhance operational efficiency and focus on its core surgical business [1][2] - The strategic realignment aims to allocate resources to areas with the highest expected returns, particularly the surgical business, which has shown consistent net revenue growth in recent years [2] - The winding down of THP is expected to continue through the end of 2025, with total cash investment in THP projected to be between $5.5 million and $6.5 million in the second half of 2025 [2] Company Overview - Sanara MedTech Inc. is a medical technology company focused on developing and commercializing technologies that improve clinical outcomes and reduce healthcare costs in the surgical market [3] - The company offers a range of surgical products, including CellerateRX Surgical Activated Collagen Powder and various advanced biologic products, primarily targeting the North American surgical tissue repair markets [3] - Sanara aims to be a leading provider of effective surgical solutions and is committed to expanding its product offerings to meet patient needs in the United States [3]